Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?

Eur J Cancer. 2017 Aug:81:240-241. doi: 10.1016/j.ejca.2017.03.017. Epub 2017 Apr 21.

Authors

Marie Kostine¹, Chloé Stavris², Laurent Chiche²

Affiliations

¹ Rheumatology Department, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France. Electronic address: marie.kostine@chu-bordeaux.fr.
² Internal Medicine Department, Hôpital Européen de Marseille, Marseille, France.

PMID: 28434854
DOI: 10.1016/j.ejca.2017.03.017

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Autoimmune Diseases / chemically induced*
Autoimmune Diseases / prevention & control
Autoimmunity / drug effects
Checklist*
Drug Eruptions / epidemiology
Drug Eruptions / prevention & control
Humans
Immunotherapy / adverse effects*
Melanoma / drug therapy*
Melanoma / pathology
Practice Patterns, Physicians' / organization & administration
Practice Patterns, Physicians' / standards*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Skin Neoplasms / drug therapy
Skin Neoplasms / pathology

Substances

Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor